A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

NCT06615479 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

440

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Multiple Myeloma (RRMM)

Interventions

DRUG: BMS-986393
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Daratumumab
DRUG: Pomalidomide
DRUG: Dexamethasone
DRUG: Carfilzomib

Sponsor

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Collaborators

[object Object]